# Personalized Medicine in Nevada COBRE

> **NIH NIH P20** · UNIVERSITY OF NEVADA LAS VEGAS · 2022 · $2,129,952

## Abstract

ABSTRACT: OVERALL
 Society is progressing beyond “trial-and-error medicine” into a new data-driven era wherein one's genetic
makeup is used to improve accuracy in medical diagnosis, prognosis, and treatment [1,2]. In President Barack
Obama's State of the Union Address on January 20, 2015, he mentioned the promise of, and future investment
in, personalized medicine. Many experts, including National Institutes of Health (NIH) Director Francis Collins,
MD, believe that what is now called personalized, precision, or individualized medicine will transform the future
of healthcare. As emerging genetic technologies gradually become the standard of care in some clinical
settings, they will continue to improve, driven largely by academic medical centers. Modern genomic and
associated bioinformatic analyses have become a staple of modern biomedical research. However, there is no
COBRE in personalized medicine, despite its growing influence. The NIH COBRE program aims to strengthen
the biomedical research infrastructure and improve competitive research in Institutional Development Award
(IDeA)–eligible states. Modern genomic and bioinformatic analyses have become a staple of modern
biomedical research. However, no COBRE exists in personalized medicine, despite its growing influence.
 UNLV is uniquely positioned to deliver on this urgent unmet need. The scientific premise of our COBRE is
to advance the use of genomics and genetics in personalized medicine through cutting-edge research
discovery and use of genetic markers, building a center of excellence that fosters new investigator
independence, and collaborating with the UNLV School of Medicine and other partners in basic and
translational research. Consistent with the goal of the NIH COBRE program i to strengthen biomedical
research infrastructure and competitive research in IDeA eligible states, we propose three aims: (1) to build a
sustained center in personalized medicine; (2) to nurture new investigator growth and independence; and (3) to
grow personalized medicine research. To accomplish these goals our proposed COBRE consists of an
Administrative core (AC), new Human Genome Data Algorithms to Analytics (HuGe DAtA) core and Genome
Analysis and Sequencing Pipeline (GASP) cores, three new investigator research projects (RPs), a mentoring
panel of internal and external experts, internal and external advisory committees, and a pilot grant program
with 12 awards intended to cultivate a pipeline of new investigators. The leadership and mentoring teams have
current research focused on the personalized medicine theme, steady NIH research funding, and a strong
mentoring history.
 This COBRE will establish a foundation to launch medical genetics clinical services and a future
educational program in clinical genetics through its collaboration with the UNLV School of Medicine, and
through a collaborative educational program in genetic counseling in the School of Nursing. Similar outcomes
were leveraged by previo...

## Key facts

- **NIH application ID:** 10458476
- **Project number:** 5P20GM121325-05
- **Recipient organization:** UNIVERSITY OF NEVADA LAS VEGAS
- **Principal Investigator:** MARTIN R SCHILLER
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,129,952
- **Award type:** 5
- **Project period:** 2018-06-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10458476

## Citation

> US National Institutes of Health, RePORTER application 10458476, Personalized Medicine in Nevada COBRE (5P20GM121325-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10458476. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*